公开(公告)号：US20200376045A1

公开(公告)日：2020-12-03

申请号：US16786079

申请日：2020-02-10

Applicant: DUPONT NUTRITION BIOSCIENCES APS

Inventor： Heli Anglenius ,  Kirsti Tiihonen ,  Nina Rautonen ,  Arthur Ouwehand

IPC: A61K35/741 ,  A61K31/205 ,  A61K35/745 ,  A61K35/747 ,  A61K35/744

Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.

公开(公告)号：US10555977B2

公开(公告)日：2020-02-11

申请号：US15963493

申请日：2018-04-26

Applicant: DUPONT NUTRITION BIOSCIENCES APS

Inventor： Heli Anglenius ,  Kirsti Tiihonen ,  Nina Rautonen ,  Arthur Ouwehand

IPC: A61K35/741 ,  A61K31/205 ,  A61K35/745 ,  A61K35/747 ,  A61K35/744

Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.